Definitive Healthcare (NASDAQ:DH) Cut to “Buy” at Wall Street Zen

Wall Street Zen downgraded shares of Definitive Healthcare (NASDAQ:DH) from a strong-buy rating to a buy rating in a research note issued to investors on Sunday.

A number of other equities analysts also recently weighed in on DH. Morgan Stanley reaffirmed an “underperform” rating and issued a $3.50 target price on shares of Definitive Healthcare in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Barclays lowered their target price on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research note on Monday, December 8th. Finally, William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Definitive Healthcare presently has a consensus rating of “Hold” and a consensus target price of $3.94.

Definitive Healthcare Trading Up 3.0%

DH stock opened at $2.79 on Friday. The business has a fifty day moving average price of $2.66 and a 200 day moving average price of $3.42. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.60 and a quick ratio of 1.60. Definitive Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $5.68. The stock has a market capitalization of $394.39 million, a price-to-earnings ratio of -1.67 and a beta of 1.60.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, November 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.The company had revenue of $60.05 million for the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. Analysts expect that Definitive Healthcare will post 0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in DH. Raymond James Financial Inc. acquired a new stake in Definitive Healthcare in the second quarter worth $32,000. Farther Finance Advisors LLC acquired a new stake in shares of Definitive Healthcare in the 2nd quarter valued at about $33,000. Savant Capital LLC bought a new stake in Definitive Healthcare in the 2nd quarter valued at about $45,000. Los Angeles Capital Management LLC bought a new stake in Definitive Healthcare in the 2nd quarter valued at about $51,000. Finally, Ariadne Wealth Management LP acquired a new position in Definitive Healthcare during the 3rd quarter worth approximately $54,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.